For Life Sciences

Ready-to-send pipeline for life science reps

By the time topline Phase 2 data hits Endpoints, buying conversations have started — partnerships, lab purchases, CRO contracts. Tnuki reads the leading indicators, like PDUFA dates, leadership moves, and social signals, and drops your Plays for the day: priority accounts, contacts, and outreach drafted around the moment.

Try Tnuki free Start for free. No signup, no credit card.
Today's Plays
Oncology · Spatial Biology · Rare Disease
From 847 stories analyzed overnight
MON, APR 14
3 plays
+ 4 to know about
Reach out now
Review & send →
Rashid Kumar To: Rashid Kumar, VP Translational Oncology, Gilead
“With Tubulis closing, curious how target-expression validation and companion-Dx workflows are evolving across the combined ADC pipeline…”
What triggered this
Gilead to acquire ADC specialist Tubulis for up to $5B
Apr 14 — $3.15B upfront validates continued ADC spend. Integration expands target-validation footprint; IHC, companion-Dx, and target-expression workflows in scope. Gilead press · Endpoints News
Reach out now
Review & send →
Jeff Tanaka To: Jeff Tanaka, Dir. Translational Science, Avidity
“Saw Endpoints on the AOC012 pull-in. The thing that keeps coming up in AOC programs is target-tissue expression and antibody-uptake reproducibility…”
What triggered this
Avidity Biosciences Phase 2a moved up on FDA calendar
Apr 13 — AOC012 accelerated to Q3. Translational team hiring 4 roles in San Diego. Endpoints News · LinkedIn req
Reach out now
Review & send →
James Chen To: James Chen, Sr. Dir. Translational Medicine, Bristol-Myers
“Saw the expanded C4 deal — curious how target-tissue expression and substrate-validation needs are shifting as the degrader pipeline scales…”
What triggered this
Bristol-Myers × C4 Therapeutics expand protein-degrader collaboration
Apr 12 — $200M upfront doubles BMS's TPD footprint. Translational team hiring 6 roles; platform buildout referenced in 10-Q. BMS press · 10-Q filing
Good to know
Cogent Biosciences 8-K signals shortened cash runway ahead of bezuclastinib readout
Apr 11 — Capital raise or partnership window opening before the Phase 3 SUMMIT readout in mast-cell disease. SEC filing · BioPharma Dive
Regeneron breaks ground on $90M Tarrytown biomarker lab
Apr 10 — VP Biomarkers posted about vendor demos. Platform-evaluation window opening Q2. Regeneron press · LinkedIn
Illumina Q1 beat; clinical and applied-genomics ARR up 22%
Apr 9 — FFPE oncology-Dx demand pressing through Q2 as translational labs scale. Bioinformatics hiring surge in San Diego. Q1 earnings · STAT News
Reach out now
Review & send →
Rashid Kumar To: Rashid Kumar, VP Translational Oncology, Gilead
“With Tubulis closing, curious how target-expression validation and companion-Dx workflows are evolving across the combined ADC pipeline…”
What triggered this
Gilead to acquire ADC specialist Tubulis for up to $5B
Apr 14 — $3.15B upfront validates continued ADC spend. Integration expands target-validation footprint; IHC, companion-Dx, and target-expression workflows in scope. Gilead press · Endpoints News
Reach out now
Review & send →
Jeff Tanaka To: Jeff Tanaka, Dir. Translational Science, Avidity
“Saw Endpoints on the AOC012 pull-in. The thing that keeps coming up in AOC programs is target-tissue expression and antibody-uptake reproducibility…”
What triggered this
Avidity Biosciences Phase 2a moved up on FDA calendar
Apr 13 — AOC012 accelerated to Q3. Translational team hiring 4 roles in San Diego. Endpoints News · LinkedIn req
Reach out now
Review & send →
James Chen To: James Chen, Sr. Dir. Translational Medicine, Bristol-Myers
“Saw the expanded C4 deal — curious how target-tissue expression and substrate-validation needs are shifting as the degrader pipeline scales…”
What triggered this
Bristol-Myers × C4 Therapeutics expand protein-degrader collaboration
Apr 12 — $200M upfront doubles BMS's TPD footprint. Translational team hiring 6 roles; platform buildout referenced in 10-Q. BMS press · 10-Q filing
Good to know
Cogent Biosciences 8-K signals shortened cash runway ahead of bezuclastinib readout
Apr 11 — Capital raise or partnership window opening before the Phase 3 SUMMIT readout in mast-cell disease. SEC filing · BioPharma Dive
Regeneron breaks ground on $90M Tarrytown biomarker lab
Apr 10 — VP Biomarkers posted about vendor demos. Platform-evaluation window opening Q2. Regeneron press · LinkedIn
Illumina Q1 beat; clinical and applied-genomics ARR up 22%
Apr 9 — FFPE oncology-Dx demand pressing through Q2 as translational labs scale. Bioinformatics hiring surge in San Diego. Q1 earnings · STAT News

Life sciences deals close around a Phase 3 readout, an 8-K, or a new lab build — not quarter-ends.

By the time topline Phase 2 data hits the company press wire, the licensing window has already closed. By the time a VP Translational hire is announced, the procurement cycle has started. By the time an 8-K hits EDGAR, the deal is already signed.

Tnuki reads the leading indicators — PDUFA dates, in-licensing rumors, translational hiring surges, patent grants, SEC filings — and surfaces accounts moving toward a real platform decision or services engagement. Not keyword-matched, not intent-scored. Read overnight, matched to your target list, delivered before standup.

Signals that matter

Every Phase readout, every 8-K, every translational hire — tracked for you.

Tnuki watches 1,000+ of sources — from Business Wire to trade journals to LinkedIn — and matches signals to your target list before you see them.

Clinical & Regulatory
Phase transitions & readouts
Phase 1→2, 2→3 moves, interim analyses, topline readouts.
PDUFA dates & AdCom meetings
FDA calendar moves, briefing documents, advisory committee votes.
Breakthrough / Fast Track / Orphan
Regulatory designations that predict accelerated timelines.
Trial pause / restart / termination
Clinical holds, enrollment restarts, early stops for efficacy.
EMA & CHMP activity
European approval filings, positive CHMP opinions, conditional authorizations.
Financial & Pipeline
Funding rounds
Series B+, private placements, reverse mergers, IPO filings.
Going-concern & 8-K filings
Capital-raise windows, auditor language shifts, disclosure red flags.
Patent cliff / LOE dates
Loss-of-exclusivity timelines that force pipeline reinvestment.
Leadership & Facilities
CMO & scientific leadership hires
CMO, CSO, VP Translational, VP Biomarkers transitions.
New labs & biomanufacturing
Biomarker centers, CGT manufacturing, translational cores.
Therapeutic-area hiring clusters
6+ parallel roles in Phase 3 oncology, CGT ops, rare disease.

Five agents, one industry

How each Tnuki agent works for life sciences.

Tnuki's five AI agents run against your life sciences target list — reading the signals that matter, verifying the contacts, drafting the outreach grounded in the actual science.

Intelligence Agent

Every morning, a brief of your accounts' overnight clinical readouts, FDA moves, and pipeline shifts — ranked by proximity to a platform or services evaluation.

Monday 6 AM: Cogent's pre-readout cash-runway 8-K, Gilead's Tubulis close, Avidity's Phase 2a pull-in — all three synthesized with "why timely" and source links, ready before your first meeting.

Tnuki Signal Agent

24/7 scan across 1,000+ sources for the signals that move your market: PDUFA dates, Phase 3 readouts, ADC / CGT deals, translational hires, going-concern filings.

Cogent's 8-K with cash-runway language appeared in EDGAR at 9:47 AM. You saw it surfaced in your feed at 9:52, matched against your target list, with a source link to the filing.

Contact Agent

Verified contacts for VP Translational Medicine, Chief Medical Officer, Head of Biomarkers, BD / Licensing Directors — the roles that actually evaluate your platform or services.

Waterfall tried HunterMail → LeadMagic → FindyMail → Prospeo. Priya Varma's email at Regeneron resolved via live-web fallback to the team bio page.

Drafting Agent

Emails grounded in the specific readout, facility build, or licensing deal. No "I noticed your company" — every draft references the ADC close, the Phase 2 data, the Tarrytown lab.

“With Tubulis closing, curious how target-expression validation and companion-Dx workflows are evolving across the combined ADC pipeline…” — drafted in 5 seconds, source-cited to the press release.

Concierge Chat

Ask in plain English. Get verified pipeline back in one answer — no filter forms, no dashboards, no stack to manage.

“Find VPs of Translational Medicine at Series C+ oncology biotechs in the Boston / Bay Area with a Phase 3 in the next 12 months” — 18 verified contacts, drafts ready, in one query.

Who you sell to

Your ICP, already on Tnuki's target list.

Life sciences selling means landing in front of the specific scientific and translational roles that evaluate your offering. Tnuki is built around those personas — and the accounts they run.

Target personas

  • VP / Head of Translational Medicine
  • Chief Medical Officer
  • VP / Head of Biomarkers & Precision Medicine
  • Head of Companion Diagnostics
  • Head of Clinical Operations
  • Head of Discovery / SVP Research
  • VP Bioinformatics / Computational Biology
  • BD / Licensing / Corporate Development Director
  • VP Clinical Development
  • Chief Scientific Officer
Target applications
Oncology / ADC Immuno-Oncology CGT & Gene Editing Rare Disease Neuroscience Immunology

Example companies on your target list

Biotech Startups & Emerging Biopharma
ModernaModerna BioNTechBioNTech AlnylamAlnylam Beam TherapeuticsBeam Therapeutics
Big Pharma
PfizerPfizer Johnson & JohnsonJohnson & Johnson NovartisNovartis RocheRoche
CROs & CDMOs
IQVIAIQVIA LabcorpLabcorp Charles RiverCharles River LonzaLonza
Medical Device & Diagnostics
MedtronicMedtronic AbbottAbbott Thermo FisherThermo Fisher DanaherDanaher
Academic Research & Hospitals
StanfordStanford HarvardHarvard Mayo ClinicMayo Clinic Johns HopkinsJohns Hopkins

Why life sciences reps switch

Built around clinical milestones.

What you're using What you actually get Tnuki instead
Manual research 30-60 min/account. Multiply by hundreds. Doesn't scale. One chat for qualified prospects in <60 seconds.
ZoomInfo / Apollo Strong contacts. Weak on clinical pipeline, trial timing, and therapeutic-area context. Verified contacts plus their clinical-milestone triggers.
Google Alerts Keyword dump across every outlet. No target list matching. 47 emails a day. Readouts, licensing, leadership signals — matched to your accounts.
LinkedIn Sales Nav Job-change alerts only. Easy to miss a CMO transition. 30+ signal types auto-matched — hires, readouts, filings, conference presentations.
ClinicalTrials.gov watching By the time a trial posts, the CRO decision is already made. Leading indicators: TA-specific hiring surges, trade-journal scoops, patent filings.

Frequently asked

Common questions about Tnuki for life sciences

Can I scope Tnuki to a specific therapeutic area?
Yes. Just tell Tnuki in plain English what you care about — oncology ADCs, cell and gene therapy, spatial biology, rare disease — and it tracks those signals for you. No keyword lists or boolean filters. Ranking adapts to your ICP and the signals you actually act on.
How early does Tnuki catch clinical signals compared to ClinicalTrials.gov?
Clinical trial listings are already late — by the time a trial posts, the CRO decision is made. Tnuki watches leading indicators: hiring surges in therapeutic areas, press releases about trial design, conference presentations, SEC disclosures, patent filings. Most show up weeks or months before a ClinicalTrials.gov listing.
Does Tnuki cover private biotech pre-IPO?
Yes. Private companies often show up first on LinkedIn hiring signals, conference presentations, patent grants, and trade-journal scoops. Tnuki watches all of those sources equally, so coverage for a Series B private company is often as strong as for a public one.
Can I monitor specific trials by NCT number?
Yes. Add NCT numbers to your target list and Tnuki surfaces any related press, LinkedIn, or SEC activity — along with the hiring and facility signals that typically surround an active program.
How does Tnuki handle the difference between early-stage discovery and late-stage commercial?
Ranking accounts for pipeline stage. A Series A CGT company and a $50B pharma company get their own relevance scores for your ICP — so a Series A facility build and an LOE date both rise to the top when they matter to your target list.
What happens if a signal involves non-public information?
Tnuki only reads publicly available sources — press releases, SEC filings, LinkedIn, X, trade journals, hiring boards, patent offices, conference programs. No MNPI, no gray areas, no scraped personal data.

Signal-based prospecting for Life Sciences

Signals Tnuki watches for Life Sciences sellers, 24/7.

Every play surfaces from a real public event — not a static list. Across 1,000+ sources, the agent reads the trigger events that move life sciences buying conversations forward.

Try Tnuki free See what Tnuki surfaces for your target list today. No signup, no credit card.

Other industries

Built for every go-to-market.

SaaS

Funding rounds, product launches, and leadership moves across your TAM, delivered daily.

Learn more →

Marketing & Analytics

Campaign launches, MarTech stack moves, and CMO transitions in real time.

Learn more →

Finance

Regulatory moves, funding activity, and leadership shifts at banks, asset managers, and fintechs.

Learn more →

Healthcare

Provider consolidations, payer moves, and clinical leadership transitions.

Learn more →

Cybersecurity

Breaches, CISO transitions, and compliance deadlines driving security spend.

Learn more →

Reveal your ideal prospects.

Find your ideal prospects in under a minute for free.

Get my new pipeline Or talk to a human →